0000000000543804

AUTHOR

Bernard A. Fox

showing 2 related works from this author

MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.

2018

Abstract To build a catalog of peptides presented by breast cancer cells, we undertook systematic MHC class I immunoprecipitation followed by elution of MHC class I-loaded peptides in breast cancer cells. We determined the sequence of 3196 MHC class I ligands representing 1921 proteins from a panel of 20 breast cancer cell lines. After removing duplicate peptides, i.e., the same peptide eluted from more than one cell line, the total number of unique peptides was 2740. Of the unique peptides eluted, more than 1750 had been previously identified, and of these, sixteen have been shown to be immunogenic. Importantly, half of these immunogenic peptides were shared between different breast cancer…

0301 basic medicineProteomicsPlant BiologyPeptideLigandsBiochemistryEpitopeAnalytical ChemistryEpitopesBreast cancerT cell-mediated immune responseHLA Antigens2.1 Biological and endogenous factorsAetiologyCancerchemistry.chemical_classificationAntigen PresentationTumorbiologyBiochemistry & Molecular BiologyBiophysicsBreast NeoplasmsArticleCell LineVaccine Related03 medical and health sciencesImmune systemBreast cancerAntigenAntigens NeoplasmCell Line TumorMHC class ImedicineGeneticsHumansAmino Acid SequenceAntigensMHC class I-restricted peptidesTumor associated antigensPreventionHistocompatibility Antigens Class ICancermedicine.diseaseHigh-Throughput Screening Assays030104 developmental biologychemistryCell cultureNeo-antigensMutationbiology.proteinCancer researchNeoplasmImmunizationBiochemistry and Cell Biology
researchProduct

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

2011

Abstract Purpose: To facilitate development of innovative immunotherapy approaches, especially for treatment concepts exploiting the potential benefits of personalized therapy, there is a need to develop and validate tools to identify patients who can benefit from immunotherapy. Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements. Experimental Design: The iSBTc-SITC (International Society for Biological Therapy of Cancer-Society for Immunotherapy of Cancer), FDA (Food and Drug Administration), and NCI (National Cancer Institute) partnered to address these issues for immunotherapy of cancer. Here…

Cancer ResearchPathologymedicine.medical_specialtyHealth Planning Guidelinesmedicine.medical_treatmentConsensus Development Conferences as TopicStandardized testImmune monitoringt-cell immunity cytokine flow-cytometry cancer vaccine consortium colony-stimulating factor b elispot assay phase-ii trial dendritic cells clinical-trials hiv vaccine harmonization guidelinesMedical OncologyArticleFood and drug administrationNeoplasmsmedicineBiomarkers TumorHumansMedical physicsPersonalized therapySocieties MedicalAntitumor immunitybusiness.industryQuality assessmentUnited States Food and Drug AdministrationCancerInternational AgenciesImmunotherapymedicine.diseaseNational Cancer Institute (U.S.)United StatesOncologyPractice Guidelines as TopicImmunotherapybusiness
researchProduct